Alnylam CEO John Maraganore – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.
You may also be interested in...
Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results
The RNA interference-focused biotech will bring the rest of its pipeline forward with subcutaneous technology now that it has been validated in human studies, but the company will continue to pursue approval of its lead candidate as an infusion product.
Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis
U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.
Silence Therapeutics Raising $8.8M To Send RNAi Drug To Phase IIa
With a deeply discounted subscription and open share offering, the U.K.'s RNAi specialist, Silence Therapeutics, hopes to reach proof of concept with its lead product candidate.